Malignant mesothelioma

Common Name(s)

Malignant mesothelioma

Malignant mesothelioma is an aggressive neoplasm of the serosal lining of the chest etiologically linked to asbestos. It is diagnosed in approximately 2,000 to 3,000 individuals annually in the United States, most of whom die within 2 years of diagnosis (summary by {6:Bott et al., 2011}). See also {614327} for a tumor predisposition syndrome that may contribute to the development of malignant mesothelioma upon asbestos exposure and is caused by germline mutation in the BAP1 gene ({603089}) on chromosome 3p21.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Malignant mesothelioma" for support, advocacy or research.

Logo
Mesothelioma Applied Research Foundation

The Mesothelioma Applied Research Foundation is the nonprofit collaboration of patients and families, physicians, advocates, and researchers dedicated to eradicating the life-ending and vicious effects of mesothelioma. We believe in a cure for meso. Given the human toll of suffering the disease causes, the compassion and energy of the meso community, the moral, legal and economic aspects of asbestos, and the benefits of meso research to cancer research generally, we believe that the resources to accomplish this cure are available and must be mobilized. We seek to marshal and utilize these resources responsibly, as effectively as possible, with financial transparency and by adhering to health policy guidelines that foster ethical clinical and administrative practices, and ethical decision making to: • Offer hope and support to patients and families by educating them on the disease, helping them to obtain the most up-to-date information on treatment options and to connect with meso tr

Last Updated: 1 Mar 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Malignant mesothelioma" for support, advocacy or research.

Logo
Mesothelioma Applied Research Foundation

The Mesothelioma Applied Research Foundation is the nonprofit collaboration of patients and families, physicians, advocates, and researchers dedicated to eradicating the life-ending and vicious effects of mesothelioma. We believe in a cure for meso. Given the human toll of suffering the disease causes, the compassion and energy of the meso community, the moral, legal and economic aspects of asbestos, and the benefits of meso research to cancer research generally, we believe that the resources to accomplish this cure are available and must be mobilized. We seek to marshal and utilize these resources responsibly, as effectively as possible, with financial transparency and by adhering to health policy guidelines that foster ethical clinical and administrative practices, and ethical decision making to: • Offer hope and support to patients and families by educating them on the disease, helping them to obtain the most up-to-date information on treatment options and to connect with meso tr

http://www.curemeso.org

Last Updated: 1 Mar 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Malignant mesothelioma" returned 1044 free, full-text research articles on human participants. First 3 results:

A Proteomic Analysis of the Malignant Mesothelioma Secretome Using iTRAQ.
 

Author(s): Jenette Creaney, Ian M Dick, Justine S Leon, Bruce W S Robinson

Journal: Cancer Genomics Proteomics. ;14(2):103-117.

 

Backgound/Aim: Malignant mesothelioma (MM) is an aggressive and fatal pleural cancer. The cell secretome offers information allowing insight into the pathogenesis of MM while offering the possibility to identify potential therapeutic targets and biomarkers. In the present study the ...

Last Updated: 7 Apr 2017

Go To URL
A Rare Case of Biphasic Malignant Peritoneal Mesothelioma with Refractory Ascites.
 

Author(s): Tomo Komaki, Hidenori Urata, Ken Mori, Akinori Iwashita, Keisuke Ikeda, Seiji Haraoka

Journal: Intern. Med.. 2017 ;56(7):861-864.

 

An 81-year-old man was admitted to our hospital with abdominal distension due to refractory ascites of unknown origin. He subsequently died of aspiration pneumonia. Autopsy revealed a diagnosis of biphasic malignant peritoneal mesothelioma (MPM) containing both epithelioid and sarcomatous ...

Last Updated: 6 Apr 2017

Go To URL
Circulating miR-132-3p as a Candidate Diagnostic Biomarker for Malignant Mesothelioma.
 

Author(s): Daniel G Weber, Katarzyna Gawrych, Swaantje Casjens, Alexander Brik, Martin Lehnert, Dirk Taeger, Beate Pesch, Jens Kollmeier, Torsten T Bauer, Georg Johnen, Thomas Brüning

Journal: Dis. Markers. 2017 ;2017():9280170.

 

The use of circulating microRNAs as biomarkers has opened new opportunities for diagnosis of cancer because microRNAs exhibit tumor-specific expression profiles. The aim of this study was the identification of circulating microRNAs in human plasma as potential biomarkers for the diagnosis ...

Last Updated: 21 Mar 2017

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Malignant mesothelioma" returned 104 free, full-text review articles on human participants. First 3 results:

Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment.
 

Author(s): Anna C Bibby, Selina Tsim, Nikolaos Kanellakis, Hannah Ball, Denis C Talbot, Kevin G Blyth, Nick A Maskell, Ioannis Psallidas

Journal: Eur Respir Rev. 2016 Dec;25(142):472-486.

 

Malignant pleural mesothelioma is an aggressive malignancy of the pleural surface, predominantly caused by prior asbestos exposure. There is a global epidemic of malignant pleural mesothelioma underway, and incidence rates are predicted to peak in the next few years.This article summarises ...

Last Updated: 1 Dec 2016

Go To URL
[Drug carrier nanosystems in malignant pleural mesothelioma].
 

Author(s): Didem Turgut Coşan, Güntülü Ak, İlknur Dağ, Ahu Soyocak, Gökhan Dikmen, Aylin Dal, Hasan V Güneş, Muzaffer Metintaş

Journal: Tuberk Toraks. 2016 Mar;64(1):60-8.

 

Malignant pleural mesothelioma (MPM), the incidence increased with each passing day, is an important lethal disease due to the limited survive with available treatment methods and with the lack of a standard treatment. Response and survive rates of cytotoxic agents which is used in ...

Last Updated: 9 Jun 2016

Go To URL
Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma: A Case Report and Literatures Review.
 

Author(s): Xu-Quan Jing, Lei Zhou, Xin-Dong Sun, Jin-Ming Yu, Xue Meng

Journal: Medicine (Baltimore). 2016 Apr;95(14):e3351.

 

Malignant pleural mesothelioma (MPM) is a lethal disease with poor prognosis. The combination of cisplatin and pemetrexed has been confirmed as the standard of care for nonoperable MPM. Data have shown that the adoption of pemetrexed maintenance therapy (PMT) following first-line ...

Last Updated: 9 Apr 2016

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
 

Status: Recruiting

Condition Summary: Mesothelioma

 

Last Updated: 30 Jun 2017

Go to URL
Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment
 

Status: Not yet recruiting

Condition Summary: Mesothelioma

 

Last Updated: 28 Mar 2016

Go to URL
A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)
 

Status: Recruiting

Condition Summary: Pleural Mesothelioma; Peritoneal Mesothelioma

 

Last Updated: 26 Oct 2015

Go to URL